Yuyu Pharma, Inc. (000220.KS)
KRW 4640.0
(2.09%)
KRW 4640.0
(2.09%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 364.53 Million KRW | -208.27% |
| 2022 | 691.74 Million KRW | -73.93% |
| 2021 | 2.65 Billion KRW | -57.69% |
| 2020 | 6.27 Billion KRW | -22.34% |
| 2019 | 8.07 Billion KRW | 51.57% |
| 2018 | 5.32 Billion KRW | 49.3% |
| 2017 | 3.56 Billion KRW | -4.46% |
| 2016 | 3.73 Billion KRW | 131.44% |
| 2015 | 1.61 Billion KRW | 17.71% |
| 2014 | 1.37 Billion KRW | -21.89% |
| 2013 | 1.75 Billion KRW | -52.81% |
| 2012 | 3.71 Billion KRW | 104.43% |
| 2011 | 1.81 Billion KRW | 40.64% |
| 2010 | 1.29 Billion KRW | 120.1% |
| 2009 | 587.71 Million KRW | 110.25% |
| 2008 | -5.73 Billion KRW | -157.31% |
| 2007 | 10 Billion KRW | -23.46% |
| 2006 | 13.07 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 4.06 Billion KRW | -5.31% |
| 2024 Q1 | 4.66 Billion KRW | 1956.41% |
| 2023 Q3 | -1.51 Billion KRW | -297.32% |
| 2023 Q4 | -251.3 Million KRW | 83.36% |
| 2023 FY | -748.94 Million KRW | -208.27% |
| 2023 Q1 | 1.97 Billion KRW | 2236.03% |
| 2023 Q2 | -380.17 Million KRW | -119.27% |
| 2022 Q1 | 979.74 Million KRW | 415.51% |
| 2022 Q2 | 505.54 Million KRW | -48.4% |
| 2022 FY | 691.74 Million KRW | -73.93% |
| 2022 Q4 | -92.35 Million KRW | 86.83% |
| 2022 Q3 | -701.18 Million KRW | -238.7% |
| 2021 Q1 | 456.44 Million KRW | 766.25% |
| 2021 FY | 2.65 Billion KRW | -57.69% |
| 2021 Q2 | 470.25 Million KRW | 3.03% |
| 2021 Q3 | 583.99 Million KRW | 24.19% |
| 2021 Q4 | -310.52 Million KRW | -153.17% |
| 2020 Q3 | 1.5 Billion KRW | -9.94% |
| 2020 FY | 6.27 Billion KRW | -22.34% |
| 2020 Q4 | 52.69 Million KRW | -96.5% |
| 2020 Q2 | 1.67 Billion KRW | -45.01% |
| 2020 Q1 | 3.04 Billion KRW | 72.07% |
| 2019 Q4 | 1.76 Billion KRW | 14.21% |
| 2019 Q1 | 1.89 Billion KRW | 42.81% |
| 2019 Q3 | 1.54 Billion KRW | -45.91% |
| 2019 Q2 | 2.86 Billion KRW | 50.57% |
| 2019 FY | 8.07 Billion KRW | 51.57% |
| 2018 Q2 | 920.82 Million KRW | -62.5% |
| 2018 Q1 | 2.45 Billion KRW | 0.0% |
| 2018 FY | 5.32 Billion KRW | 49.3% |
| 2018 Q3 | 620.55 Million KRW | -32.61% |
| 2018 Q4 | 1.33 Billion KRW | 114.38% |
| 2017 Q3 | 1.43 Billion KRW | -11.0% |
| 2017 FY | 3.56 Billion KRW | -4.46% |
| 2017 Q1 | 1.72 Billion KRW | -3.77% |
| 2017 Q2 | 1.61 Billion KRW | -6.31% |
| 2016 Q2 | -710.29 Million KRW | -125.78% |
| 2016 Q1 | 2.75 Billion KRW | 3542.02% |
| 2016 FY | 3.73 Billion KRW | 131.44% |
| 2016 Q4 | 1.79 Billion KRW | 91.95% |
| 2016 Q3 | 932.56 Million KRW | 231.29% |
| 2015 Q1 | 1.52 Billion KRW | 99.65% |
| 2015 FY | 1.61 Billion KRW | 17.71% |
| 2015 Q4 | 75.64 Million KRW | 180.09% |
| 2015 Q3 | -94.45 Million KRW | 91.58% |
| 2015 Q2 | -1.12 Billion KRW | -173.72% |
| 2014 FY | 1.37 Billion KRW | -21.89% |
| 2014 Q4 | 762.67 Million KRW | -12.81% |
| 2014 Q3 | 874.78 Million KRW | 148.89% |
| 2014 Q2 | -1.78 Billion KRW | -274.87% |
| 2014 Q1 | 1.02 Billion KRW | 148.51% |
| 2013 Q1 | 2.56 Billion KRW | 332.88% |
| 2013 Q4 | 411.71 Million KRW | 128.0% |
| 2013 Q3 | 180.58 Million KRW | 353.95% |
| 2013 Q2 | 39.78 Million KRW | -98.45% |
| 2013 FY | 1.75 Billion KRW | -52.81% |
| 2012 Q2 | 249.74 Million KRW | 0.0% |
| 2012 FY | 3.71 Billion KRW | 104.43% |
| 2012 Q1 | - KRW | -100.0% |
| 2012 Q3 | 310.98 Million KRW | 24.52% |
| 2012 Q4 | 592.73 Million KRW | 90.6% |
| 2011 Q1 | 927.93 Million KRW | -44.36% |
| 2011 FY | 1.81 Billion KRW | 40.64% |
| 2011 Q2 | 162.19 Million KRW | -82.52% |
| 2011 Q3 | 920.86 Million KRW | 467.75% |
| 2011 Q4 | 742.97 Million KRW | -19.32% |
| 2010 Q4 | 1.66 Billion KRW | 217.73% |
| 2010 FY | 1.29 Billion KRW | 120.1% |
| 2010 Q1 | 3.66 Billion KRW | 95.04% |
| 2010 Q2 | 114.43 Million KRW | -96.88% |
| 2010 Q3 | -1.41 Billion KRW | -1337.92% |
| 2009 Q1 | -3.82 Billion KRW | -23.52% |
| 2009 Q4 | 1.88 Billion KRW | 228.23% |
| 2009 Q3 | -1.46 Billion KRW | 58.03% |
| 2009 FY | 587.71 Million KRW | 110.25% |
| 2009 Q2 | -3.49 Billion KRW | 8.55% |
| 2008 FY | -5.73 Billion KRW | -157.31% |
| 2008 Q2 | 536.74 Million KRW | -48.52% |
| 2008 Q4 | -3.09 Billion KRW | -577.77% |
| 2008 Q3 | 647.86 Million KRW | 20.7% |
| 2008 Q1 | 1.04 Billion KRW | -76.32% |
| 2007 Q4 | 4.4 Billion KRW | 91.47% |
| 2007 FY | 10 Billion KRW | -23.46% |
| 2007 Q3 | 2.29 Billion KRW | 1.73% |
| 2007 Q2 | 2.25 Billion KRW | 0.0% |
| 2006 FY | 13.07 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 98.559% |
| Yuhan Corporation | 74.56 Billion KRW | 99.511% |
| Yuhan Corporation | 74.56 Billion KRW | 99.511% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 0.0% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 0.0% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 100.458% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 94.367% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 99.526% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 99.637% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 99.637% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 99.637% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 102.02% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 98.9% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | 38.877% |
| HANDOK Inc. | 12.57 Billion KRW | 97.102% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 98.257% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 118.326% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 100.972% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 100.521% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 104.7% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 98.869% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | 88.306% |
| Boryung Corporation | 68.26 Billion KRW | 99.466% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 94.737% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 98.22% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 97.46% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 97.46% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 99.152% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 99.253% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | 88.072% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 98.879% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | 62.176% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 100.769% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 100.769% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 99.337% |
| CKD Bio Corp. | -20.15 Billion KRW | 101.809% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 99.727% |
| JW Holdings Corporation | 143.66 Billion KRW | 99.746% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 90.963% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 99.838% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 96.739% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 99.852% |
| JW Lifescience Corporation | 32.09 Billion KRW | 98.864% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 100.682% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 95.825% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 98.651% |